Idarucizumab

🧮 Dose calculator

Life-threatening bleeding on anticoagulants (reversal) · Regimen source: FDA Praxbind · 2.1

• • Two 2.5 g vials consecutively (infusions or bolus). Limited data for a second 5 g. Restart anticoagulation as soon as medically appropriate; dabigatran after 24 h. FDA Praxbind · 2.1FDA Praxbind · 2.3FDA Praxbind · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Praxbind · 8.1

  “Risk Summary There are no available data on PRAXBIND use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Praxbind · 8.2

  “Because many drugs are excreted in human milk, caution should be exercised when PRAXBIND is administered to a nursing woman.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Praxbind · 8.4

  “Safety and effectiveness have not been established in pediatric patients.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Praxbind · 8.5

  “A total of 454 (90%) patients treated with idarucizumab in the case series trial were 65 years of age and older, and 318 (63%) were 75 years of age and older.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.